A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to show proof of concept that by blocking the Transforming
Growth Factor-beta signaling pathway in patients with Glioblastoma, there will be clinical
benefit.
Phase 1b: To determine the safe and tolerable dose of LY2157299 in combination with
radiochemotherapy with temozolomide for Phase 2 in patients with glioma eligible to receive
radiochemotherapy with temozolomide (e.g. newly diagnosed malignant glioma World Health
Organization Grade III and IV).
Phase 2a: To confirm the tolerability and evaluate the pharmacodynamic effect of LY2157299 in
combination with standard radiochemotherapy in patients with newly diagnosed glioblastoma.